title: Drug reaction with eosinophilia and systemic symptoms (DRESS) in a patient taking sitagliptin.
abstract: Sitagliptin is a recent oral antidiabetic drug for type 2 diabetes patients. This report is the first case of a severe drug reaction with eosinophilia and systemic symptoms (DRESS), which resolved with systemic corticosteroids. However, vigilance is necessary during the prescription of these compounds.
authors.affiliation: Service de Dermatologie, Hôpital Victor-Dupouy, 69, rue du Lt-Col-Prud'hon, 95100 Argenteuil, France. carole.sin@ch-argenteuil.fr
authors.forename: C
authors.initials: C
authors.lastname: Sin
authors.forename: E
authors.initials: E
authors.lastname: Mahé
authors.forename: M-L
authors.initials: ML
authors.lastname: Sigal
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000150:complications; D000368:Aged; D001415:Back / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D004423:Ear / Q000473:pathology; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004802:Eosinophilia / Q000139:chemically induced* / Q000150:complications; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D011241:Prednisone / Q000008:administration & dosage; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D005938:Glucocorticoids; D011719:Pyrazines; D014230:Triazoles; D000068900:Sitagliptin Phosphate; D011241:Prednisone